PharmaTelevision - Asmacure. CEO, Martin Driscoll talks about their simple new mechanism which could transform the health of patients with asthma

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Asmacure. CEO, Martin Driscoll talks about their simple new mechanism which could transform the health of patients with asthma

Visitors: You are watching a 5 minute preview.

Get more information and subscribe now

RSS

Twitter

In This Episode:

Summary
Transcript
Participants
Company

In this episode of PharmaTelevision News Review, Fintan Walton talks to Martin Driscoll, CEO of Asmacure.

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Asmacure's Lead compound for treatment of Asthma

Fintan Walton:

Hello and welcome to PharmaTelevision News Review here at BioPharm America in Boston. On this show I have Martin J. Driscoll, who is the CEO of a company called Asmacure based in Quebec City in Canada, welcome to the show.

Martin J. Driscoll:

Thank you Fintan, glad to be here.

Fintan Walton:

So Marty Driscoll, you've just joined at Asmacure but it's a company that's been established for some time, could you first of all tell us what is Asmacure about? What's the company?

Martin J. Driscoll:

Asmacure was established in 2002 the focus is the development of molecules called nicotinic receptor agonist and our focus is on inflammatory diseases , but our lead compound is right now in the clinic being tested for the treatment of asthma.

Fintan Walton:

Right, so what is it that I mean obviously there are lots of molecules out of there, lots of treatment for asthma, so what are you bringing to the asthma story that will transform the health of patients with asthma?

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Fintan Walton

Dr Fintan Walton is the Founder and CEO of PharmaVentures . After completing his doctoral research on the genetics of cell proliferation at the University of Michigan(US)and Trinity College (Dublin, Ireland), Dr Walton gained broad commercial experience in biotechnology in management positions at Bass and Celltech plc (1982-1992).

Martin J Driscoll

CEO

Martin J. Driscoll was appointed Chief Executive Officer of Asmacure on April 13, 2011. Mr. Driscoll has more than 30 years of experience in the pharmaceutical industry. Mr. Driscoll's experience in the pharmaceutical industry includes senior roles in General Management, Commercial Operations, and Business Development for both privately-held and publicly-traded life sciences commercial- and development-stage companies. Mr. Driscoll has also previously served as a Director on the Boards of three private and public biopharmaceutical development companies. Previously, Mr. Driscoll was the Chief Executive Officer and a Director of Javelin Pharmaceuticals Inc, a developer of acute care pain products, from March 2008 until July 2010 when he engineered the successful merger of Javelin Pharmaceuticals Inc with Hospira Inc. During his career, Mr. Driscoll has also worked at Schering-Plough, ViroPharma Inc and Reliant Pharmaceuticals. In 2007, Mr. Driscoll co-founded Pear Tree Pharmaceuticals, a privately-held developer of women's healthcare products. During his career at Schering-Plough, Mr. Driscoll was the General Manager of Key Pharmaceuticals, the Schering-Plough Unit responsible for all respiratory products in the U.S. Mr. Driscoll has been involved with or led the commercialization of four blockbuster therapies, the direct negotiation of multiple transactions, licensing and M&A, and the successful submission of multiple major product regulatory filings. Mr. Driscoll holds a B.Sc. in Communications from the University of Texas at Austin. He is a Board member of the Epilepsy Foundation of America.

PharmaVentures

PharmaVentures is a corporate finance and transactions advisory firm that has served hundreds of clients worldwide in relation to their strategic deal making in the pharmaceutical, life science and healthcare sectors. Our key offerings include: Transactions / deal negotiations; Product / technology valuations; Deal term advice; Due diligence & expert reports; Strategy formulation; Alliance management; and Expert opinion for litigation/arbitration cases. PharmaVentures provides the global expertise to ensure our clients generate the highest possible return on investment from all their deal making activities. We have experience of all therapeutic areas and can offer advice on both product and technology commercialisation.

Asmacure

Asmacure Ltee is a clinical-stage biopharmaceutical company focused on the development of novel, proprietary nicotinic receptor agonist compounds for the treatment of inflammatory diseases . The company's lead compound, ASM-024, was the first nicotinic receptor agonist to enter clinical testing for the treatment of asthma. Asmacure was founded in 2002 and is based in Quebec City, Quebec, Canada.